13therapeutics, Inc.

13Therapeutics, Inc is a spin out from the Oregon Health and Science University (OHSU) and has exclusively licensed peptides on a world-wide basis. U.S. patents claiming the composition of the lead peptide and its use in all inflammatory conditions involving Toll-Like Receptor (TLR) signaling have been issued, and several additional patents have been issued.  The company performs all in vitro testing in-house and subcontracts with OHSU and other academic instututions for animal model testing.  The company is privately funded and has received NIH peer reviewed grants, including multiple Phase II and Phase II SBIR grants.